Mitomycin vs lobaplatin after colorectal surgery with heated chemotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial compares two chemotherapy drugs—mitomycin and lobaplatin—given into the abdomen while it is warmed, after planned surgery for advanced colon cancer. It may help reduce cancer coming back after “curative” surgery in people without spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon cancer confirmed as adenocarcinoma by pathology (lab test on tissue)
- Your cancer is T3 or higher but has not spread to distant organs, and you can have “radical” surgery
- No prior cancer treatment (like chemo or chemoradiation) before starting this trial
- Your blood and organ tests are strong enough (blood counts, liver, and kidney function meet set limits)
- You are age 18–75, and you can safely undergo surgery (heart/lung conditions must be acceptable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three chemotherapy drugs (liposomal irinotecan, oxaliplatin, and capecitabine) given directly into the liver blood vessel after surgery to remove colorectal cancer that has spread to the liver. The goal is to reduce the chance of cancer coming back.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This Phase 3 trial studies whether adding targeted therapy to standard chemotherapy after surgery helps people with stage T3-4, N2 colon cancer live longer or have fewer cancer returns. You would be assigned to receive chemotherapy with targeted therapy or chemotherapy alone, based on the study plan.
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.